| Assay ID | Title | Year | Journal | Article |
|---|
| AID158065 | In vitro concentration required to inhibit the rate of dog platelet aggregation (in platelet rich plasma) by 50% was determined in presence of 10 ug/mL of collagen and 1 uM of epinephrine | 1995 | Journal of medicinal chemistry, Aug-18, Volume: 38, Issue:17
| Non-peptide fibrinogen receptor antagonists. 7. Design and synthesis of a potent, orally active fibrinogen receptor antagonist. |
| AID158228 | Concentration required to inhibit platelet aggregation by 50% | 1995 | Journal of medicinal chemistry, Aug-18, Volume: 38, Issue:17
| Non-peptide fibrinogen receptor antagonists. 7. Design and synthesis of a potent, orally active fibrinogen receptor antagonist. |
| AID158064 | In vitro concentration required to inhibit the rate of dog platelet aggregation (in platelet rich plasma) by 50% was determined in presence of 10 uM of ADP and 1 uM of epinephrine | 1995 | Journal of medicinal chemistry, Aug-18, Volume: 38, Issue:17
| Non-peptide fibrinogen receptor antagonists. 7. Design and synthesis of a potent, orally active fibrinogen receptor antagonist. |
| AID60229 | Ex vivo antiplatelet activity was assessed following oral administration at a dose of 1 mg/kg to dogs in the presence of 10 uM of ADP and 1 uM of epinephrine at 20 min | 1995 | Journal of medicinal chemistry, Aug-18, Volume: 38, Issue:17
| Non-peptide fibrinogen receptor antagonists. 7. Design and synthesis of a potent, orally active fibrinogen receptor antagonist. |
| AID216430 | Whole blood platelet count was determined as delta% from baseline | 1995 | Journal of medicinal chemistry, Aug-18, Volume: 38, Issue:17
| Non-peptide fibrinogen receptor antagonists. 7. Design and synthesis of a potent, orally active fibrinogen receptor antagonist. |
| AID84818 | Inhibition of human umbilical vein endothelial cell adhesion to fibronectin | 1995 | Journal of medicinal chemistry, Aug-18, Volume: 38, Issue:17
| Non-peptide fibrinogen receptor antagonists. 7. Design and synthesis of a potent, orally active fibrinogen receptor antagonist. |
| AID216429 | Whole blood platelet count was determined in 10e3/uL | 1995 | Journal of medicinal chemistry, Aug-18, Volume: 38, Issue:17
| Non-peptide fibrinogen receptor antagonists. 7. Design and synthesis of a potent, orally active fibrinogen receptor antagonist. |
| AID60364 | Ex vivo antiplatelet activity was assessed following oral administration at a dose of 1 mg/kg to dogs in the presence of 10 uM of collagen and 1 uM of epinephrine at 300 min | 1995 | Journal of medicinal chemistry, Aug-18, Volume: 38, Issue:17
| Non-peptide fibrinogen receptor antagonists. 7. Design and synthesis of a potent, orally active fibrinogen receptor antagonist. |
| AID60362 | Ex vivo antiplatelet activity was assessed following oral administration at a dose of 1 mg/kg to dogs in the presence of 10 uM of collagen and 1 uM of epinephrine at 20 min | 1995 | Journal of medicinal chemistry, Aug-18, Volume: 38, Issue:17
| Non-peptide fibrinogen receptor antagonists. 7. Design and synthesis of a potent, orally active fibrinogen receptor antagonist. |
| AID220877 | Binding affinity to resting form of alpha IIb/beta3 integrin by flow cytometry using fluorescein ligand L-726,745 displacement from human platelets. | 2000 | Bioorganic & medicinal chemistry letters, Sep-04, Volume: 10, Issue:17
| Nonpeptide GPIIB/IIIA receptor antagonists. Part 21: C-6 flexibility and amide bond orientation are important factors in determining the affinity of compounds for activated or resting platelet receptors. |
| AID222789 | Inhibition of aggregation of human gel-filtered platelets measured by light transmittance method at 37 degrees C. | 2000 | Bioorganic & medicinal chemistry letters, Sep-04, Volume: 10, Issue:17
| Nonpeptide GPIIB/IIIA receptor antagonists. Part 21: C-6 flexibility and amide bond orientation are important factors in determining the affinity of compounds for activated or resting platelet receptors. |
| AID158234 | In vitro concentration required to inhibit the rate of human platelet aggregation (in platelet rich plasma) by 50% was determined in presence of 10 uM of epinephrine | 1995 | Journal of medicinal chemistry, Aug-18, Volume: 38, Issue:17
| Non-peptide fibrinogen receptor antagonists. 7. Design and synthesis of a potent, orally active fibrinogen receptor antagonist. |
| AID60366 | Ex vivo antiplatelet activity was assessed following oral administration at a dose of 1 mg/kg to dogs in the presence of 10 uM of collagen and 1 uM of epinephrine at 40 min | 1995 | Journal of medicinal chemistry, Aug-18, Volume: 38, Issue:17
| Non-peptide fibrinogen receptor antagonists. 7. Design and synthesis of a potent, orally active fibrinogen receptor antagonist. |
| AID73005 | Displacement of [125I]L-692884 from purified Fibrinogen Receptor activated by coating onto yttrium silicate | 1997 | Journal of medicinal chemistry, Jun-06, Volume: 40, Issue:12
| Non-peptide glycoprotein IIb/IIIa inhibitors. 17. Design and synthesis of orally active, long-acting non-peptide fibrinogen receptor antagonists. |
| AID60236 | Ex vivo antiplatelet activity was assessed following oral administration at a dose of 1 mg/kg to dogs in the presence of 10 uM of ADP and 1 uM of epinephrine at 70 min | 1995 | Journal of medicinal chemistry, Aug-18, Volume: 38, Issue:17
| Non-peptide fibrinogen receptor antagonists. 7. Design and synthesis of a potent, orally active fibrinogen receptor antagonist. |
| AID60233 | Ex vivo antiplatelet activity was assessed following oral administration at a dose of 1 mg/kg to dogs in the presence of 10 uM of ADP and 1 uM of epinephrine at 350 min | 1995 | Journal of medicinal chemistry, Aug-18, Volume: 38, Issue:17
| Non-peptide fibrinogen receptor antagonists. 7. Design and synthesis of a potent, orally active fibrinogen receptor antagonist. |
| AID32998 | Inhibition of alpha IIb beta-3 integrin mediated platelet aggregation | 2000 | Journal of medicinal chemistry, Sep-21, Volume: 43, Issue:19
| Platelet glycoprotein IIb-IIIa antagonists as prototypical integrin blockers: novel parenteral and potential oral antithrombotic agents. |
| AID233840 | Selectivity as determined by the ratio of KDs, resting receptor over activated receptor | 2000 | Bioorganic & medicinal chemistry letters, Sep-04, Volume: 10, Issue:17
| Nonpeptide GPIIB/IIIA receptor antagonists. Part 21: C-6 flexibility and amide bond orientation are important factors in determining the affinity of compounds for activated or resting platelet receptors. |
| AID60240 | Ex vivo antiplatelet activity was assessed following oral administration at a dose of 1 mg/kg to dogs in the presence of 10 uM of collagen and 1 uM of epinephrine at 150 min | 1995 | Journal of medicinal chemistry, Aug-18, Volume: 38, Issue:17
| Non-peptide fibrinogen receptor antagonists. 7. Design and synthesis of a potent, orally active fibrinogen receptor antagonist. |
| AID158232 | In vitro concentration required to inhibit the rate of human platelet aggregation (in platelet rich plasma) by 50% was determined in presence of 0.5 U/mL of thrombin and 1 mM GPRP | 1995 | Journal of medicinal chemistry, Aug-18, Volume: 38, Issue:17
| Non-peptide fibrinogen receptor antagonists. 7. Design and synthesis of a potent, orally active fibrinogen receptor antagonist. |
| AID60232 | Ex vivo antiplatelet activity was assessed following oral administration at a dose of 1 mg/kg to dogs in the presence of 10 uM of ADP and 1 uM of epinephrine at 300 min | 1995 | Journal of medicinal chemistry, Aug-18, Volume: 38, Issue:17
| Non-peptide fibrinogen receptor antagonists. 7. Design and synthesis of a potent, orally active fibrinogen receptor antagonist. |
| AID60228 | Ex vivo antiplatelet activity was assessed following oral administration at a dose of 1 mg/kg to dogs in the presence of 10 uM of ADP and 1 uM of epinephrine at 150 min | 1995 | Journal of medicinal chemistry, Aug-18, Volume: 38, Issue:17
| Non-peptide fibrinogen receptor antagonists. 7. Design and synthesis of a potent, orally active fibrinogen receptor antagonist. |
| AID158235 | In vitro concentration required to inhibit the rate of human platelet aggregation (in platelet rich plasma) by 50% was determined in presence of 10 ug/mL of collagen | 1995 | Journal of medicinal chemistry, Aug-18, Volume: 38, Issue:17
| Non-peptide fibrinogen receptor antagonists. 7. Design and synthesis of a potent, orally active fibrinogen receptor antagonist. |
| AID18841 | Oral bioavailability in dog | 2000 | Journal of medicinal chemistry, Sep-21, Volume: 43, Issue:19
| Platelet glycoprotein IIb-IIIa antagonists as prototypical integrin blockers: novel parenteral and potential oral antithrombotic agents. |
| AID60363 | Ex vivo antiplatelet activity was assessed following oral administration at a dose of 1 mg/kg to dogs in the presence of 10 uM of collagen and 1 uM of epinephrine at 250 min | 1995 | Journal of medicinal chemistry, Aug-18, Volume: 38, Issue:17
| Non-peptide fibrinogen receptor antagonists. 7. Design and synthesis of a potent, orally active fibrinogen receptor antagonist. |
| AID60239 | Ex vivo antiplatelet activity was assessed following oral administration at a dose of 1 mg/kg to dogs in the presence of 10 uM of collagen and 1 uM of epinephrine at 1440 min | 1995 | Journal of medicinal chemistry, Aug-18, Volume: 38, Issue:17
| Non-peptide fibrinogen receptor antagonists. 7. Design and synthesis of a potent, orally active fibrinogen receptor antagonist. |
| AID158063 | In vitro concentration required to inhibit the rate of chimp platelet aggregation (in platelet rich plasma) by 50% was determined in presence of 20 uM of ADP | 1995 | Journal of medicinal chemistry, Aug-18, Volume: 38, Issue:17
| Non-peptide fibrinogen receptor antagonists. 7. Design and synthesis of a potent, orally active fibrinogen receptor antagonist. |
| AID33002 | Dissociation constant for alpha IIb beta-3 integrin activated platelets | 2000 | Journal of medicinal chemistry, Sep-21, Volume: 43, Issue:19
| Platelet glycoprotein IIb-IIIa antagonists as prototypical integrin blockers: novel parenteral and potential oral antithrombotic agents. |
| AID225573 | Inhibition of platelet aggregation after administration of 30 ug/kg iv bolus to dogs within first 1-15 min | 2000 | Journal of medicinal chemistry, Sep-21, Volume: 43, Issue:19
| Platelet glycoprotein IIb-IIIa antagonists as prototypical integrin blockers: novel parenteral and potential oral antithrombotic agents. |
| AID60241 | Ex vivo antiplatelet activity was assessed following oral administration at a dose of 1 mg/kg to dogs in the presence of 10 uM of collagen and 1 uM of epinephrine at 200 min | 1995 | Journal of medicinal chemistry, Aug-18, Volume: 38, Issue:17
| Non-peptide fibrinogen receptor antagonists. 7. Design and synthesis of a potent, orally active fibrinogen receptor antagonist. |
| AID220879 | Competition with [1251]L-692,884 for binding to purified alpha IIb/beta3 integrin, activated by coating onto yttrium silicate scintillation proximity assay fluomicrospheres. | 2000 | Bioorganic & medicinal chemistry letters, Sep-04, Volume: 10, Issue:17
| Nonpeptide GPIIB/IIIA receptor antagonists. Part 21: C-6 flexibility and amide bond orientation are important factors in determining the affinity of compounds for activated or resting platelet receptors. |
| AID216431 | Whole blood platelet count was determined in 10e3/uL | 1995 | Journal of medicinal chemistry, Aug-18, Volume: 38, Issue:17
| Non-peptide fibrinogen receptor antagonists. 7. Design and synthesis of a potent, orally active fibrinogen receptor antagonist. |
| AID33001 | Dissociation constant for alpha IIb beta-3 integrin rested platelets | 2000 | Journal of medicinal chemistry, Sep-21, Volume: 43, Issue:19
| Platelet glycoprotein IIb-IIIa antagonists as prototypical integrin blockers: novel parenteral and potential oral antithrombotic agents. |
| AID158062 | In vitro concentration required to inhibit the rate of chimp platelet aggregation (in platelet rich plasma) by 50% was determined in presence of 10 ug/mL of collagen | 1995 | Journal of medicinal chemistry, Aug-18, Volume: 38, Issue:17
| Non-peptide fibrinogen receptor antagonists. 7. Design and synthesis of a potent, orally active fibrinogen receptor antagonist. |
| AID60365 | Ex vivo antiplatelet activity was assessed following oral administration at a dose of 1 mg/kg to dogs in the presence of 10 uM of collagen and 1 uM of epinephrine at 350 min | 1995 | Journal of medicinal chemistry, Aug-18, Volume: 38, Issue:17
| Non-peptide fibrinogen receptor antagonists. 7. Design and synthesis of a potent, orally active fibrinogen receptor antagonist. |
| AID160073 | Peak % inhibition of ADP induced platelet aggregation 70 minutes after administration of 200 ug/kg by gastric lavage | 1997 | Journal of medicinal chemistry, Jun-06, Volume: 40, Issue:12
| Non-peptide glycoprotein IIb/IIIa inhibitors. 17. Design and synthesis of orally active, long-acting non-peptide fibrinogen receptor antagonists. |
| AID60226 | Ex vivo antiplatelet activity was assessed following oral administration at a dose of 1 mg/kg to dogs in the presence of 10 uM of ADP and 1 uM of epinephrine at 0 min | 1995 | Journal of medicinal chemistry, Aug-18, Volume: 38, Issue:17
| Non-peptide fibrinogen receptor antagonists. 7. Design and synthesis of a potent, orally active fibrinogen receptor antagonist. |
| AID84819 | Inhibition of human umbilical vein endothelial cell adhesion to vitronectin | 1995 | Journal of medicinal chemistry, Aug-18, Volume: 38, Issue:17
| Non-peptide fibrinogen receptor antagonists. 7. Design and synthesis of a potent, orally active fibrinogen receptor antagonist. |
| AID60227 | Ex vivo antiplatelet activity was assessed following oral administration at a dose of 1 mg/kg to dogs in the presence of 10 uM of ADP and 1 uM of epinephrine at 1440 min | 1995 | Journal of medicinal chemistry, Aug-18, Volume: 38, Issue:17
| Non-peptide fibrinogen receptor antagonists. 7. Design and synthesis of a potent, orally active fibrinogen receptor antagonist. |
| AID60231 | Ex vivo antiplatelet activity was assessed following oral administration at a dose of 1 mg/kg to dogs in the presence of 10 uM of ADP and 1 uM of epinephrine at 250 min | 1995 | Journal of medicinal chemistry, Aug-18, Volume: 38, Issue:17
| Non-peptide fibrinogen receptor antagonists. 7. Design and synthesis of a potent, orally active fibrinogen receptor antagonist. |
| AID84817 | Inhibition of human umbilical vein endothelial cell adhesion to fibrinogen | 1995 | Journal of medicinal chemistry, Aug-18, Volume: 38, Issue:17
| Non-peptide fibrinogen receptor antagonists. 7. Design and synthesis of a potent, orally active fibrinogen receptor antagonist. |
| AID158233 | In vitro concentration required to inhibit the rate of human platelet aggregation (in platelet rich plasma) by 50% was determined in presence of 10 uM of ADP | 1995 | Journal of medicinal chemistry, Aug-18, Volume: 38, Issue:17
| Non-peptide fibrinogen receptor antagonists. 7. Design and synthesis of a potent, orally active fibrinogen receptor antagonist. |
| AID60230 | Ex vivo antiplatelet activity was assessed following oral administration at a dose of 1 mg/kg to dogs in the presence of 10 uM of ADP and 1 uM of epinephrine at 200 min | 1995 | Journal of medicinal chemistry, Aug-18, Volume: 38, Issue:17
| Non-peptide fibrinogen receptor antagonists. 7. Design and synthesis of a potent, orally active fibrinogen receptor antagonist. |
| AID60235 | Ex vivo antiplatelet activity was assessed following oral administration at a dose of 1 mg/kg to dogs in the presence of 10 uM of ADP and 1 uM of epinephrine at 480 min | 1995 | Journal of medicinal chemistry, Aug-18, Volume: 38, Issue:17
| Non-peptide fibrinogen receptor antagonists. 7. Design and synthesis of a potent, orally active fibrinogen receptor antagonist. |
| AID92981 | In vitro inhibition of human gel-filtered platelets | 1996 | Journal of medicinal chemistry, Nov-08, Volume: 39, Issue:23
| Non-peptide glycoprotein IIb/IIIa antagonists. 11. Design and in vivo evaluation of 3,4-dihydro-1 (1H)-isoquinolinone-based antagonists and ethyl ester prodrugs. |
| AID60215 | Compound was tested for inhibition of extent of ADP-induced platelet aggregation between 1 and 15 min at 30 ug/Kg intravenous bolus in dogs | 1997 | Journal of medicinal chemistry, Jun-06, Volume: 40, Issue:12
| Non-peptide glycoprotein IIb/IIIa inhibitors. 17. Design and synthesis of orally active, long-acting non-peptide fibrinogen receptor antagonists. |
| AID60234 | Ex vivo antiplatelet activity was assessed following oral administration at a dose of 1 mg/kg to dogs in the presence of 10 uM of ADP and 1 uM of epinephrine at 40 min | 1995 | Journal of medicinal chemistry, Aug-18, Volume: 38, Issue:17
| Non-peptide fibrinogen receptor antagonists. 7. Design and synthesis of a potent, orally active fibrinogen receptor antagonist. |
| AID92849 | Concentration required to inhibit the rate of platelet aggregation by 50% was determined with human gel filtered platelets (GFP) | 1995 | Journal of medicinal chemistry, Aug-18, Volume: 38, Issue:17
| Non-peptide fibrinogen receptor antagonists. 7. Design and synthesis of a potent, orally active fibrinogen receptor antagonist. |
| AID60238 | Ex vivo antiplatelet activity was assessed following oral administration at a dose of 1 mg/kg to dogs in the presence of 10 uM of collagen and 1 uM of epinephrine at 0 min | 1995 | Journal of medicinal chemistry, Aug-18, Volume: 38, Issue:17
| Non-peptide fibrinogen receptor antagonists. 7. Design and synthesis of a potent, orally active fibrinogen receptor antagonist. |
| AID73139 | Displacement of L-736,622 from purified resting Fibrinogen Receptor | 1997 | Journal of medicinal chemistry, Jun-06, Volume: 40, Issue:12
| Non-peptide glycoprotein IIb/IIIa inhibitors. 17. Design and synthesis of orally active, long-acting non-peptide fibrinogen receptor antagonists. |
| AID60367 | Ex vivo antiplatelet activity was assessed following oral administration at a dose of 1 mg/kg to dogs in the presence of 10 uM of collagen and 1 uM of epinephrine at 480 min | 1995 | Journal of medicinal chemistry, Aug-18, Volume: 38, Issue:17
| Non-peptide fibrinogen receptor antagonists. 7. Design and synthesis of a potent, orally active fibrinogen receptor antagonist. |
| AID92238 | Inhibition of aggregation of human gel-filtered platelets was measured by light transmittance method. | 1997 | Journal of medicinal chemistry, Jun-06, Volume: 40, Issue:12
| Non-peptide glycoprotein IIb/IIIa inhibitors. 17. Design and synthesis of orally active, long-acting non-peptide fibrinogen receptor antagonists. |
| AID60368 | Ex vivo antiplatelet activity was assessed following oral administration at a dose of 1 mg/kg to dogs in the presence of 10 uM of collagen and 1 uM of epinephrine at 70 min | 1995 | Journal of medicinal chemistry, Aug-18, Volume: 38, Issue:17
| Non-peptide fibrinogen receptor antagonists. 7. Design and synthesis of a potent, orally active fibrinogen receptor antagonist. |
| AID60237 | Ex vivo antiplatelet activity was assessed following oral administration at a dose of 1 mg/kg to dogs in the presence of 10 uM of ADP and 1 uM of epinephrine at 90 min | 1995 | Journal of medicinal chemistry, Aug-18, Volume: 38, Issue:17
| Non-peptide fibrinogen receptor antagonists. 7. Design and synthesis of a potent, orally active fibrinogen receptor antagonist. |
| AID60369 | Ex vivo antiplatelet activity was assessed following oral administration at a dose of 1 mg/kg to dogs in the presence of 10 uM of collagen and 1 uM of epinephrine at 90 min | 1995 | Journal of medicinal chemistry, Aug-18, Volume: 38, Issue:17
| Non-peptide fibrinogen receptor antagonists. 7. Design and synthesis of a potent, orally active fibrinogen receptor antagonist. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |